-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2344 Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study

Program: Oral and Poster Abstracts
Session: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical Research, Real-world evidence
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Narendranath Epperla, MD, MS1, Natalie Grover, MD2, Pallawi Torka, MD3, Reem Karmali, MD4, Kaitlin Annunzio, DO5, Marcus P. Watkins, PhD6*, Andrea Carolina Anampa-Guzmán, MD7*, Heather Reves, MS, BS8*, Montreh Tavakkoli, MD9, Beth Christian, MD10, Colin Thomas, MD11, Stefan K. Barta, MD, MS12*, Praveen Ramakrishnan Geethakumari, MD, MS8, Geoffrey Shouse, PhD, DO13, Nancy L. Bartlett, MD14 and Adam J. Olszewski, MD15

1Division of Hematology, Department of Medicine, The Ohio State University, The James Cancer Hospital and Solove Research Institute, Columbus, OH
2University of North Carolina, Chapel Hill, NC
3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
4Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
5The James Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH
6Division of Oncology, Washington University School of Medicine, St. Louis, MO
7Roswell Park Comprehensive Cancer Center, Buffalo, NY
8Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX
9Department of Medicine, Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
10Division of Hematology, The Ohio State University, Columbus, OH
11Department of Medicine, University of Pennsylvania, Philadelphia, PA
12Perelman Center for Advanced Medicine - University of Pennsylvania, Philadelphia, PA
13City of Hope Cancer Center, Duarte, CA
14Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
15Brown University, Providence, RI

Introduction
Although MZL is an indolent B-cell lymphoma typically associated with excellent overall survival (OS), a subgroup of patients (pts) experience histological transformation (HT) to an aggressive lymphoma, significantly compromising their OS. Prior studies evaluating risk factors for HT largely lacked MZL-specific clinicopathological factors such as the presence of monoclonal (M-) protein, large B-cell (LC) content in the tumor, and Ki67 expression. Attainment of complete response (CR) to first-line therapy was associated with a lower risk of HT in a single-center retrospective study (Alderuccio et al., JCO, 2018), but it remains unclear whether attainment of CR mitigates other baseline risk factors and whether its effect might reflect guarantee-time bias. Using a large multi-institutional cohort of pts with MZL we investigated a comprehensive set of risk factors for HT and described its outcomes.

Methods
This multicenter, retrospective cohort study included adult pts with MZL treated between 2010 and 2020 at 10 US medical centers. Patients with HT recorded within 2 months after MZL diagnosis were excluded. We used penalized LASSO regression to select variables with the strongest association with HT in competing risk models for cumulative incidence function (CIF), reporting subhazard ratios (SHR) with 95% confidence intervals (CI). Candidate variables included age, sex, performance status, B symptoms, stage, bone marrow involvement, LDH, MZL subtype, gastric location, baseline hemoglobin, albumin, presence of M-protein, Ki67 and CD5 expression, LC tumor content, and complex cytogenetics. Missing data were accounted for using multiple imputation. Association of HT with CR was examined in models accounting for guarantee-time bias using landmark analysis. OS after HT was evaluated using stratification based on the time between MZL diagnosis and HT.

Results
The study included 917 pts (median age 63 years; 56% women; 59% stage 3/4) with 58% extranodal, 22% nodal and 20% splenic MZL. LDH was elevated at diagnosis in 24%, M-protein was present in 46%, LC in 12%, and high (≥20%, cutoff based on Epperla et al., ASH 2023) Ki67 expression in 22%. Forty pts (4.4%) experienced HT at a median of 29 months from diagnosis (range, 2.7 to 106). The CIF of HT was 3.9% (95%CI, 2.7-5.5) at 5 years and 9.0% (95%CI, 5.8-13.0) at 10 years.

Of all candidate variables, only high Ki67 expression (SHR=2.82; 95%CI, 1.28-6.20) and presence of LC at diagnosis (SHR=2.46; 95%CI, 1.07-5.66) were consistently selected by LASSO as associated with HT. However, these two variables were highly correlated, and only high Ki67 remained significantly associated with HT in a bivariate model (HR=2.53; 95%CI, 1.13-5.65). The CIF of HT was 3.7% (95%CI, 1.9-6.5) for tumors with low, and 9.9% (95%CI, 4.6-17.6) for those with high Ki67.

Among first-line treatments for MZL, the most common were rituximab monotherapy (41%), bendamustine with rituximab (21%), and radiation therapy (18%). Attainment of CR with first-line therapy was associated with a significantly lower risk of HT using landmark analysis up to 4 months from the start of therapy (n=853, SHR=0.47; 95%CI, 0.23-0.95). However, the association was lost with longer landmarks. Attainment of CR partly mitigated the increased risk associated with high Ki67 (using landmark of ≥4 months). Pts with high Ki67 who did not attain CR had a 5-year risk of HT of 23.1% (95%CI, 8.7-41.4).

Ten (25%) of all HT events occurred during the first year since MZL diagnosis. OS after HT did not significantly differ between pts with HT ≤1 year from diagnosis (3-year OS, 55.6%, 95%CI, 20.4-80.4) and those with later HT events (3-year OS 47.1%, 95%CI, 25.3-66.2; log-rank P=0.84).

Discussion
Among baseline clinicopathologic variables, only high Ki67 expression was consistently associated with an increased risk for HT in MZL. Therefore, molecular markers (TBL1XR1, CCND3, TP53 alterations) should be incorporated into future predictive models. The increased risk associated with high Ki67 was partly mitigated by attainment of CR with (predominantly anthracycline-free) first-line treatment, suggesting that a deeper remission might be meaningful for MZL pts, particularly those with high baseline Ki67. Pts with early and later HT had similar prognoses. OS after HT in MZL remains suboptimal even with contemporary therapies, and both preventing and treating HT remain important goals for future research.

Disclosures: Epperla: Ispen: Other: Advisory Board; Lilly: Other: Advisory Board; Novartis: Consultancy; Genetech: Speakers Bureau; Beigene: Speakers Bureau. Grover: Seagen: Honoraria; Novartis: Honoraria; Regeneron: Honoraria, Research Funding; ADC Therapeutics: Honoraria; BMS: Honoraria, Research Funding; Caribou: Honoraria; Ono Pharma: Honoraria; Genentech: Honoraria; Cabaletta: Research Funding; Janssen: Honoraria; Kite: Honoraria; Sangamo: Current holder of stock options in a privately-held company. Torka: TG Therapeutics: Consultancy; Abbvie: Consultancy; ADC Therapeutics: Consultancy; Lilly Oncology: Consultancy; Genentech: Consultancy; Genmab: Consultancy; Seagen: Consultancy. Karmali: Genentech/Roche: Honoraria; Abbvie: Honoraria; BMS: Honoraria; Genmab: Honoraria; BeiGene: Speakers Bureau; Ipsen: Speakers Bureau; AstraZeneca: Speakers Bureau; Incyte: Speakers Bureau. Christian: Genentech: Research Funding; Acerta: Research Funding; Astra Zeneca: Honoraria; Ipsen: Honoraria; Millenium: Research Funding; Bristol Myers Squibb: Research Funding. Ramakrishnan Geethakumari: Ipsen Biopharma: Membership on an entity's Board of Directors or advisory committees; Ono Pharma: Membership on an entity's Board of Directors or advisory committees; Cellectar Biosciences: Membership on an entity's Board of Directors or advisory committees; ADC therapeutics: Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Consultancy; Bristol Myers Squibb: Consultancy; Regeneron Pharma: Membership on an entity's Board of Directors or advisory committees. Shouse: Abbvie: Consultancy; Beigene, Inc: Consultancy, Honoraria, Speakers Bureau; Astra Zeneca: Honoraria; Kite Pharmaceuticals: Consultancy, Honoraria, Speakers Bureau. Bartlett: Autolus: Research Funding; Washington University School of Medicine: Current Employment; ADC Therapeutics: Research Funding; Seattle Genetics: Research Funding; Foresight Diagnostics: Membership on an entity's Board of Directors or advisory committees; Millennium: Research Funding; Genmab: Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Research Funding; Roche/Genentech: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Research Funding; Kite Pharm: Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Research Funding; Forty Seven: Research Funding; Celegne: Research Funding; BMS: Research Funding. Olszewski: Genmab, Schrodinger, Genentech, Inc., Precision Biosciences, Artiva, Pfizer, Kymera Therapeutics: Research Funding; Genmab, Schrodinger, ADC Therapeutics, BeiGene, Bristol-Myers Squibb: Consultancy.

*signifies non-member of ASH